-16%

est. 2Y upside i

HealthcareSeries D+

Focus on closing, not clicking. Clarify is the joyful, autonomous CRM that helps build your pipeline, accelerate deals, handle meeting admin and update customer records—running your sales backend while you build relationships.

Rank

#3809

Sector

Health Care Technology

Est. Liquidity

~4Y

Data Quality

Data: Low

Clarify Health carries meaningful equity risk for a job candidate entering at the current $1.4B valuation: the mark is over 4 years stale and implies a 28x revenue multiple on $50M ARR that is very hard to defend in 2026's compressed SaaS pricing environment, and the $411M preference stack (29.4% of valuation) leaves common shareholders last in line on any exit below that threshold.

Last updated: May 14, 2026

Bull (20%)+80%

Clarify achieves ~40% CAGR reaching ~$100M ARR by late 2027, enabling an IPO or strategic acquisition (IQVIA, Oracle Health) at $2.0–2.5B; at a $2.5B exit, after absorbing $411M in liquidation preferences, common shareholders see roughly +80% uplift from the $1.4B grant basis. The proprietary 300M patient-journey dataset and 75% gross margins support a premium multiple if top-line growth validates the 2022 valuation.

Base (50%)-25%

Revenue grows modestly to $65–75M ARR by 2027 but no liquidity event materializes within 2 years; a likely flat or mildly down-round bridge financing (defending the $1.4B mark on $65M ARR implies ~21x revenue vs. the current 28x) dilutes common stock ~25% from the grant basis. Equity remains illiquid and the stale 2022 multiple is difficult to sustain in a repriced 2026 SaaS environment.

Bear (30%)-65%

Growth stalls below $60M ARR, forcing a down round or distressed M&A at $600–750M; after satisfying $411M in liquidation preferences, only $190–340M remains for all shareholders, leaving common stock holders with roughly 35 cents on the dollar of their $1.4B-basis equity. SoftBank Vision Fund preferred terms and potential anti-dilution provisions could further compress common-stock recovery to near zero in adverse scenarios.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Funding Intensity

29%

Total funding of $411M against a $1.4B valuation represents a 29.4% liquidation preference ratio — common stockholders receive nothing in any exit priced below $411M and see material haircuts on exits up to roughly $1.0B.

Dilution Risk

high

With no new capital since April 2022 and no profitability data disclosed, a future financing round (likely required for sustained growth and runway) will dilute existing common holders, potentially at a flat or down-round valuation.

Secondary Liquidity

limited

No secondary market data or tender offer history was identified; at 116 employees with SoftBank-backed preferred terms, informal secondary trades may exist but are likely restricted, illiquid, and priced below the stale $1.4B mark.

Engineering — 5 roles

Go-to-Market — 1 role

Product & Design — 1 role

View all 7 open roles at Clarify →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Clarify's data — designed to show you've done your homework.

  • 1

    “Since the Series D closed in April 2022 at a $1.4B valuation, what revenue and ARR milestones have you achieved since then that support or would revise that mark — and what ARR does the board consider necessary to pursue an IPO?”

  • 2

    “What percentage of revenue is outcome-based versus recurring subscription, and what is your net dollar retention and average contract value across the health system and payer customer segments?”

  • 3

    “What is the current 409A strike price, has the board discussed any secondary tender offer to provide employee liquidity, and what is the realistic timeline for a liquidity event given no new financing since April 2022?”

Community

Valuation Sentiment

Our model estimates -16% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.